AQP4 and myeloid sarcoma: In summary, a limitation in this study was that data were collected from a subset of the study population based on AQP4‐IgG positivity from laboratory testing and included only current or recently active NMOSD cases, who had been seen in MS clinics or undergone AQP4‐IgG testing.